December 3, 2018 / 9:15 AM / in 9 days

Dutch firm argenx, J&J affiliate to collaborate on cancer therapy

(Reuters) - Netherlands-based biopharmaceutical company argenx SE said it signed a deal with Cilag GmbH International, an affiliate of Johnson & Johnson’s Janssen Pharmaceutical Companies unit, to develop its Cusatuzumab drug in certain types of cancer.

The deal, which is potentially worth up to $1.6 billion, represents a global collaboration and licensing agreement for the cancer drug Cusatuzumab, the company said.

Janssen will pay argenx $300 million in upfront cash payment, while Johnson & Johnson Innovation will make an equity investment of $200 million in argenx, the company said.

The Netherlands-based company, which develops antibody-based therapies for the treatment of severe autoimmune diseases and cancer, will be eligible to receive potentially up to $1.3 billion in development, regulatory and sales milestones, it said in a statement.

Reporting by Kanishka Singh in Bengaluru; Editing by Gopakumar Warrier

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below